Migraine is an extremely disabling, common neurological disorder characterized by a
complex neurobiology, involving a series of central and peripheral nervous system areas …

Background Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …

Background Several novel treatments targeting the calcitonin gene-related peptide pathway
have been developed for migraine. We evaluated the efficacy of these medications …

Migraine is a complex condition in which genetic predisposition interacts with other
biological and environmental factors determining its course. A hyperresponsive brain cortex …

Objective While there are several trials that support the efficacy of various drugs for migraine
prophylaxis against placebo, there is limited evidence addressing the comparative safety …

Background Clinical trials and real-world studies revealed a spectrum of response to CGRP
(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at …

Background Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its
receptor (anti-CGRP (-R) mAbs) and small-molecule CGRP receptor antagonists (gepants) …

Introduction Migraine prophylactic therapy has changed over recent years with the
development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene …

The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP)
pathway, collectively called here “anti-CGRP/rec mAbs”, have dramatically improved …

Background Therapeutic options for migraine prevention in non-responders to monoclonal
antibodies (mAbs) targeting Calcitonin Gene-Related Peptide (CGRP) and its receptor are …